Excitement Over Ibrutinib Responses in Aggressive Lymphomas Medscape Since the addition of rituximab to chemotherapy, there have been no advances in the treatment of DLBCL, explained Dr. Staudt. "We are able to cure about half of all patients," he said during a press briefing, "but there are about 10000 deaths every ... |
